Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bioinformatics methods in biomarkers of preeclampsia and associated potential drug applications.
BMC Genomics
October 2022
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan Shandong, 250012, China.
Background: Preeclampsia is a pregnancy-related condition that causes high blood pressure and proteinuria after 20 weeks of pregnancy. It is linked to increased maternal mortality, organ malfunction, and foetal development limitation. In this view, there is a need critical to identify biomarkers for the early detection of preeclampsia.
View Article and Find Full Text PDFVasodilators for primary Raynaud's phenomenon.
Cochrane Database Syst Rev
May 2021
Department of Rheumatology, Gold Coast University Hospital, Southport, Australia.
Background: Numerous agents have been suggested for the symptomatic treatment of primary Raynaud's phenomenon. Apart from calcium channel blockers, which are considered to be the drugs of choice, evidence of the effects of alternative pharmacological treatments is limited. This is an update of a review first published in 2008.
View Article and Find Full Text PDFInterventions for frostbite injuries.
Cochrane Database Syst Rev
December 2020
Department of Surgery and Transplantation C2122, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Background: Frostbite is a thermal injury caused when tissue is exposed to sub-zero temperatures (in degrees Celsius) long enough for ice crystals to form in the affected tissue. Depending on the degree of tissue damage, thrombosis, ischaemia, necrosis (tissue death), gangrene and ultimately amputation may occur. Several interventions for frostbite injuries have been proposed, such as hyperbaric oxygen therapy, sympathectomy (nerve block), thrombolytic (blood-thinning) therapy and vasodilating agents such as iloprost, reserpine, pentoxifylline and buflomedil, but the benefits and harms of these interventions are unclear.
View Article and Find Full Text PDFPentoxifylline for intermittent claudication.
Cochrane Database Syst Rev
October 2020
Faculty of Pharmacy, Middle East University, Amman, Jordan.
Background: Intermittent claudication (IC) is a symptom of peripheral arterial disease (PAD) and is associated with high morbidity and mortality. Pentoxifylline, one of many drugs used to treat IC, acts by decreasing blood viscosity, improving erythrocyte flexibility, and promoting microcirculatory flow and tissue oxygen concentration. Many studies have evaluated the efficacy of pentoxifylline in treating people with PAD, but results of these studies are variable.
View Article and Find Full Text PDFDrug treatments in patients with cardiac diseases and epilepsy.
Acta Neurol Scand
July 2020
Science of Health Department, School of Medicine, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Objective: Comorbidity between epilepsy and heart diseases is frequent.
Methods: All drugs classified within the group of drugs for cardiovascular system according to the Anatomical Therapeutic Chemical (ATC) classification system were reviewed for their effects on seizures or epilepsy.
Results: Several agents showed antiseizure properties in animal models of seizures and/or in patients with epilepsy and only few were proconvulsant.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!